NASDAQ:GNMK - GenMark Diagnostics Stock Price, Price Target & More

$6.57 +0.25 (+3.96 %)
(As of 04/26/2018 09:30 AM ET)
Previous Close$6.32
Today's Range$6.20 - $6.63
52-Week Range$3.63 - $13.67
Volume447,700 shs
Average Volume389,187 shs
Market Capitalization$350.21 million
P/E Ratio-5.43
Dividend YieldN/A
Beta0.6

About GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics logoGenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNMK
CUSIPN/A
Phone760-448-4300

Debt

Debt-to-Equity Ratio0.29%
Current Ratio3.44%
Quick Ratio3.04%

Price-To-Earnings

Trailing P/E Ratio-5.43
Forward P/E Ratio-8.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$52.52 million
Price / Sales6.93
Cash FlowN/A
Price / CashN/A
Book Value$1.29 per share
Price / Book5.09

Profitability

EPS (Most Recent Fiscal Year)($1.21)
Net Income$-61,850,000.00
Net Margins-117.77%
Return on Equity-91.14%
Return on Assets-53.72%

Miscellaneous

Employees517
Outstanding Shares55,410,000

How to Become a New Pot Stock Millionaire

GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc (NASDAQ:GNMK) issued its quarterly earnings results on Tuesday, February, 27th. The medical equipment provider reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.01. The medical equipment provider had revenue of $16.02 million for the quarter, compared to analyst estimates of $15.82 million. GenMark Diagnostics had a negative return on equity of 91.14% and a negative net margin of 117.77%. View GenMark Diagnostics' Earnings History.

When is GenMark Diagnostics' next earnings date?

GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for GenMark Diagnostics.

What price target have analysts set for GNMK?

6 equities research analysts have issued 12-month target prices for GenMark Diagnostics' shares. Their forecasts range from $8.00 to $13.00. On average, they anticipate GenMark Diagnostics' share price to reach $10.60 in the next twelve months. View Analyst Ratings for GenMark Diagnostics.

What are Wall Street analysts saying about GenMark Diagnostics stock?

Here are some recent quotes from research analysts about GenMark Diagnostics stock:
  • 1. Needham & Company LLC analysts commented, "On 4/19/18, bioMerieux announced its 1Q18 results, which included 47% FilmArray growth fueled partly by the severe flu season. bioMerieux’s BioFire FilmArray is the market-leading syndromic panel molecular testing system. We estimate that bioMerieux ended 1Q18 with a FilmArray installed base of ~6,750. We believe that bioMerieux’s strong FilmArray growth indicates that the syndromic panel testing market remains significantly under-penetrated and we have increased confidence that GNMK can exceed the 1Q18 revenue consensus when it reports on 5/1/18." (4/24/2018)
  • 2. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (1/25/2018)
  • 3. BTIG Research analysts commented, "The fact that ACOR announced this morning that it will discontinue the tozadenant program (stopping dosing in all currently enrolled studies) came as little surprise following last week’s disclosure of safety issues (our thoughts here). Timing was the only marginal surprise, but based on additional analyses, the company determined that the recently instituted weekly white blood cell count screening may not be adequate to fully ensure the safety of patients. Though this morning’s headline has little incremental impact, it does highlight the added pressure on Inbrija (which is delayed itself following the RTF earlier this year) and formally removes the potential for near- term leverage in the business. Maintain Neutral." (11/20/2017)

Who are some of GenMark Diagnostics' key competitors?

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the folowing people:
  • James Charles Fox Ph.D., Independent Chairman of the Board (Age 63)
  • Hany Massarany, President, Chief Executive Officer, Director (Age 55)
  • Scott Mendel, Chief Financial Officer (Age 50)
  • Eric Stier, Senior Vice President, General Counsel, Secretary (Age 41)
  • Jennifer Anne Williams, Senior Vice President - Human Resources (Age 43)
  • Michael W. Gleeson, Senior Vice President, North American Commercial Operations (Age 42)
  • Jon Faiz Kayyem Ph.D., Senior Vice President - Research and Development (Age 53)
  • James B. McNally, Senior Vice President, Marketing and Business Development (Age 37)
  • Michael S. Kagnoff, Director (Age 48)
  • Daryl Jay Faulkner, Independent Director (Age 68)

Has GenMark Diagnostics been receiving favorable news coverage?

Media coverage about GNMK stock has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GenMark Diagnostics earned a coverage optimism score of 0.15 on Accern's scale. They also gave media stories about the medical equipment provider an impact score of 45.34 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are GenMark Diagnostics' major shareholders?

GenMark Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include PRUDENTIAL FINANCIAL INC (3.10%). Company insiders that own GenMark Diagnostics stock include Eric Stier, Hany Massarany, Ingo Chakravarty, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.

How do I buy shares of GenMark Diagnostics?

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GNMK stock can currently be purchased for approximately $6.57.

How big of a company is GenMark Diagnostics?

GenMark Diagnostics has a market capitalization of $350.21 million and generates $52.52 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]


MarketBeat Community Rating for GenMark Diagnostics (GNMK)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GenMark Diagnostics (NASDAQ:GNMK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for GenMark Diagnostics in the last 12 months. Their average twelve-month price target is $10.60, suggesting that the stock has a possible upside of 61.34%. The high price target for GNMK is $13.00 and the low price target for GNMK is $8.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.833.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.60$10.60$11.80$14.40
Price Target Upside: 61.34% upside118.56% upside150.53% upside83.67% upside

GenMark Diagnostics (NASDAQ:GNMK) Consensus Price Target History

Price Target History for GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics (NASDAQ:GNMK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018Needham & Company LLCReiterated RatingBuy$11.00MediumView Rating Details
2/28/2018Canaccord GenuityLower Price TargetBuy -> Buy$10.00 -> $8.00MediumView Rating Details
1/16/2018BTIG ResearchSet Price TargetBuy$11.00LowView Rating Details
11/3/2017CowenReiterated RatingBuy$10.00N/AView Rating Details
11/3/2017Raymond JamesReiterated RatingOutperform -> Market PerformN/AView Rating Details
9/18/2017Bank of AmericaInitiated CoverageBuy -> Buy$13.00HighView Rating Details
7/29/2016JPMorgan ChaseBoost Price TargetOverweight$10.00 -> $13.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

GenMark Diagnostics (NASDAQ:GNMK) Earnings History and Estimates Chart

Earnings by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics (NASDAQ:GNMK) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.23)($0.23)($0.23)

GenMark Diagnostics (NASDAQ GNMK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018($0.22)N/AView Earnings Details
2/27/2018Q4 2017($0.26)($0.2650)$15.82 million$16.02 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.26)($0.28)$14.56 million$11.60 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.32)($0.37)$12.44 million$12.36 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.28)($0.30)$12.55 million$12.54 millionViewListenView Earnings Details
2/28/2017Q416($0.27)($0.27)$15.03 million$14.90 millionViewListenView Earnings Details
11/3/2016Q316($0.31)($0.27)$10.36 million$10.80 millionViewN/AView Earnings Details
7/28/2016Q216($0.33)($0.30)$9.62 million$12.50 millionViewListenView Earnings Details
5/3/2016Q116($0.29)($0.30)$10.67 million$11.06 millionViewN/AView Earnings Details
2/23/2016Q415($0.27)($0.21)$12.34 million$13.20 millionViewListenView Earnings Details
10/27/2015Q315($0.31)($0.27)$8.24 million$8.80 millionViewListenView Earnings Details
8/6/2015Q215($0.31)($0.29)$7.59 million$7.65 millionViewN/AView Earnings Details
5/5/2015Q115($0.24)($0.24)$10.10 million$10.10 millionViewN/AView Earnings Details
2/24/2015Q414($0.28)($0.21)$9.83 million$9.83 millionViewN/AView Earnings Details
10/30/2014Q314($0.32)($0.23)$5.80 million$6.30 millionViewN/AView Earnings Details
8/11/2014Q214($0.29)($0.27)$4.79 million$6.55 millionViewN/AView Earnings Details
5/6/2014Q114($0.25)($0.21)$6.40 million$7.91 millionViewN/AView Earnings Details
3/11/2014Q413($0.22)($0.21)$6.06 million$6.45 millionViewN/AView Earnings Details
11/12/2013Q313($0.27)($0.24)$4.60 million$4.64 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.26)($0.25)$5.05 million$5.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$9.53 million$11.10 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.23)($0.13)ViewN/AView Earnings Details
11/7/2012Q3 2012($0.20)($0.20)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.27)($0.26)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.28)($0.28)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.26)($0.27)ViewN/AView Earnings Details
11/10/2011($0.32)($0.31)ViewN/AView Earnings Details
8/5/2011($0.45)($0.39)ViewN/AView Earnings Details
5/9/2011($0.49)($0.56)ViewN/AView Earnings Details
3/3/2011($0.52)($0.30)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.50)($0.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

GenMark Diagnostics (NASDAQ:GNMK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

GenMark Diagnostics (NASDAQ GNMK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.50%
Insider Trading History for GenMark Diagnostics (NASDAQ:GNMK)
Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

GenMark Diagnostics (NASDAQ GNMK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/12/2018Eric StierSVPSell10,000$5.46$54,600.00197,502View SEC Filing  
3/2/2018Eric StierSVPSell341$4.00$1,364.00207,502View SEC Filing  
3/1/2018Michael KagnoffDirectorBuy10,000$4.22$42,200.0074,413View SEC Filing  
2/26/2018Hany MassaranyInsiderSell17,300$4.17$72,141.00722,190View SEC Filing  
2/26/2018Jennifer Anne WilliamsSVPSell4,911$4.17$20,478.87227,122View SEC Filing  
2/26/2018Scott MendelCFOSell6,275$4.17$26,166.75246,161View SEC Filing  
2/21/2018Jennifer Anne WilliamsSVPSell5,147$4.40$22,646.80149,342View SEC Filing  
2/20/2018Hany MassaranyInsiderSell6,584$4.37$28,772.08357,190View SEC Filing  
2/20/2018Scott MendelCFOSell2,304$4.37$10,068.48129,161View SEC Filing  
2/14/2018Scott MendelCFOSell1,391$4.54$6,315.14131,465View SEC Filing  
2/2/2018Eric StierSVPSell401$5.13$2,057.13134,108View SEC Filing  
2/2/2018Hany MassaranyInsiderSell1,252$5.13$6,422.76View SEC Filing  
2/2/2018Scott MendelCFOSell258$5.13$1,323.54132,856View SEC Filing  
1/23/2018Eric StierSVPSell4,000$5.05$20,200.00134,509View SEC Filing  
12/4/2017Michael GleesonSVPSell499$4.70$2,345.30287,140View SEC Filing  
11/20/2017Hany MassaranyInsiderSell8,252$4.74$39,114.48362,957View SEC Filing  
11/20/2017Jennifer Anne WilliamsSVPSell2,719$4.74$12,888.06152,709View SEC Filing  
11/20/2017Scott MendelCFOSell2,879$4.74$13,646.46133,114View SEC Filing  
11/14/2017Scott MendelCFOSell1,777$4.71$8,369.67135,993View SEC Filing  
11/6/2017Michael KagnoffDirectorBuy20,000$4.13$82,600.0064,413View SEC Filing  
11/2/2017Eric StierSVPSell367$7.24$2,657.08141,112View SEC Filing  
11/2/2017Hany MassaranyInsiderSell1,588$7.24$11,497.12371,209View SEC Filing  
11/2/2017Scott MendelCFOSell326$7.24$2,360.24137,770View SEC Filing  
10/2/2017Eric StierSVPSell2,750$9.60$26,400.00View SEC Filing  
9/15/2017Jennifer Anne WilliamsSVPSell38,681$9.08$351,223.48155,889View SEC Filing  
9/11/2017Michael KagnoffDirectorBuy2,500$9.15$22,875.0044,413View SEC Filing  
9/5/2017Eric StierSVPSell311$9.75$3,032.25144,229View SEC Filing  
8/21/2017Hany MassaranyInsiderSell8,311$9.45$78,538.95372,797View SEC Filing  
8/21/2017Michael GleesonSVPSell1,933$9.45$18,266.85291,223View SEC Filing  
8/21/2017Scott MendelCFOSell2,898$9.45$27,386.10138,096View SEC Filing  
8/15/2017Scott MendelCFOSell1,752$10.16$17,800.32140,994View SEC Filing  
8/2/2017Hany MassaranyInsiderSell1,629$10.33$16,827.57View SEC Filing  
8/2/2017Jon Faiz KayyemSVPSell138$10.33$1,425.54200,719View SEC Filing  
8/2/2017Scott MendelCFOSell333$10.33$3,439.89142,746View SEC Filing  
6/2/2017Michael GleesonSVPSell357$12.89$4,601.73293,565View SEC Filing  
5/19/2017Hany MassaranyInsiderSell8,239$12.89$106,200.71View SEC Filing  
5/19/2017Michael GleesonSVPSell1,916$12.89$24,697.24293,922View SEC Filing  
5/19/2017Scott MendelCFOSell2,135$12.89$27,520.15143,079View SEC Filing  
5/16/2017Scott MendelCFOSell1,268$13.43$17,029.24View SEC Filing  
5/2/2017Eric StierSVPSell362$13.34$4,829.08148,825View SEC Filing  
5/2/2017Hany MassaranyInsiderSell1,571$13.34$20,957.14View SEC Filing  
5/2/2017Scott MendelCFOSell232$13.34$3,094.88162,529View SEC Filing  
3/3/2017Michael GleesonSVPSell353$12.29$4,338.37296,757View SEC Filing  
2/21/2017Hany MassaranyInsiderSell33,537$10.08$338,052.96View SEC Filing  
2/21/2017Jon Faiz KayyemSVPSell5,250$10.08$52,920.00154,079View SEC Filing  
2/21/2017Scott MendelCFOSell8,595$10.08$86,637.60102,761View SEC Filing  
2/2/2017Hany MassaranyInsiderSell1,142$11.58$13,224.36View SEC Filing  
2/2/2017Jennifer Anne WilliamsSVPSell332$11.58$3,844.56161,930View SEC Filing  
2/2/2017Scott MendelCFOSell235$11.58$2,721.30View SEC Filing  
1/19/2017Hany MassaranyInsiderSell27,124$12.47$338,236.28298,500View SEC Filing  
1/19/2017Michael GleesonSVPSell9,569$12.47$119,325.43252,558View SEC Filing  
1/19/2017Scott MendelCFOSell9,098$12.47$113,452.06142,058View SEC Filing  
12/5/2016Jennifer Anne WilliamsSVPSell336$11.31$3,800.16View SEC Filing  
12/2/2016Michael GleesonSVPSell357$11.30$4,034.10View SEC Filing  
11/22/2016Michael KagnoffDirectorBuy2,000$11.80$23,600.0035,048View SEC Filing  
11/14/2016Michael KagnoffDirectorBuy2,000$12.50$25,000.0033,048View SEC Filing  
11/2/2016Hany MassaranyInsiderSell1,148$10.30$11,824.40View SEC Filing  
11/2/2016Michael GleesonSVPSell400$10.30$4,120.00245,653View SEC Filing  
9/7/2016Hany MassaranyInsiderSell1,186$8.69$10,306.34View SEC Filing  
9/7/2016Jennifer Anne WilliamsSVPSell523$8.69$4,544.87164,080View SEC Filing  
9/2/2016Jon Faiz KayyemSVPSell133$8.62$1,146.46152,437View SEC Filing  
8/29/2016Jennifer Anne WilliamsSVPSell24,172$8.63$208,604.36164,937View SEC Filing  
8/22/2016Michael GleesonSVPSell7,500$9.00$67,500.00246,934View SEC Filing  
8/12/2016Lisa M GilesDirectorBuy823$9.40$7,736.2016,710View SEC Filing  
8/2/2016Eric StierSVPSell367$9.88$3,625.96110,681View SEC Filing  
8/2/2016Hany MassaranyInsiderSell1,147$9.88$11,332.36View SEC Filing  
6/7/2016Hany MassaranyCEOSell1,188$8.98$10,668.24292,640View SEC Filing  
6/7/2016Michael GleesonSVPSell868$8.80$7,638.40255,358View SEC Filing  
6/3/2016Ingo ChakravartySVPSell184$8.53$1,569.52139,229View SEC Filing  
5/9/2016Ingo ChakravartySVPSell582$5.42$3,154.44137,913View SEC Filing  
5/2/2016Eric StierSVPSell363$5.79$2,101.77111,560View SEC Filing  
5/2/2016Hany MassaranyCEOSell1,160$5.79$6,716.40295,765View SEC Filing  
3/10/2016Michael KagnoffDirectorBuy2,500$4.90$12,250.0022,761View SEC Filing  
3/7/2016Hany MassaranyCEOSell1,193$5.76$6,871.68298,768View SEC Filing  
3/7/2016Michael GleesonSVPSell559$5.76$3,219.84254,598View SEC Filing  
3/2/2016Eric StierSVPSell365$4.87$1,777.55112,189View SEC Filing  
2/9/2016Ingo ChakravartySVPSell697$5.04$3,512.8858,379View SEC Filing  
2/3/2016Hany MassaranyCEOSell9,173$4.99$45,773.27View SEC Filing  
2/3/2016Michael GleesonSVPSell3,083$4.99$15,384.17176,353View SEC Filing  
1/21/2016Hany MassaranyCEOSell648$6.80$4,406.4079,557View SEC Filing  
1/21/2016Michael GleesonSVPSell227$6.80$1,543.60179,436View SEC Filing  
12/8/2015Eric StierSVPSell240$7.26$1,742.4039,660View SEC Filing  
12/8/2015Hany MassaranyCEOSell1,735$7.26$12,596.1079,557View SEC Filing  
12/3/2015Hany MassaranyCEOSell3,571$7.71$27,532.4182,682View SEC Filing  
12/3/2015Michael GleesonSVPSell1,664$7.62$12,679.68179,707View SEC Filing  
11/3/2015Lisa M GilesDirectorBuy4,000$6.60$26,400.008,213View SEC Filing  
10/30/2015Michael KagnoffDirectorBuy5,000$6.70$33,500.0020,261View SEC Filing  
10/30/2015Scott MendelCFOBuy10,000$6.47$64,700.0052,145View SEC Filing  
10/29/2015Daryl FaulknerDirectorBuy4,000$7.33$29,320.0053,013View SEC Filing  
9/15/2015Jennifer Anne WilliamsSVPSell14,245$9.98$142,165.10118,547View SEC Filing  
9/14/2015Jennifer Anne WilliamsSVPSell9,245$10.00$92,450.00118,547View SEC Filing  
9/11/2015Hany MassaranyCEOSell1,683$9.64$16,224.1289,557View SEC Filing  
9/11/2015Jennifer Anne WilliamsSVPSell18,280$9.99$182,617.20132,792View SEC Filing  
9/4/2015Jennifer Anne WilliamsSVPSell1,867$9.59$17,904.53151,072View SEC Filing  
9/2/2015Hany MassaranyCEOSell3,865$9.62$37,181.3092,682View SEC Filing  
8/24/2015Scott MendelCFOBuy10,000$9.10$91,000.0052,145View SEC Filing  
6/16/2015Hany MassaranyCEOSell1,698$9.12$15,485.76View SEC Filing  
6/4/2015Michael GleesonSVPSell1,595$9.55$15,232.25View SEC Filing  
6/3/2015Hany MassaranyCEOSell3,486$9.47$33,012.42View SEC Filing  
4/9/2015Hany MassaranyCEOSell5,942$11.52$68,451.84View SEC Filing  
3/13/2015Jennifer Anne WilliamsSVPSell30,000$12.56$376,800.00View SEC Filing  
3/11/2015Hany MassaranyCEOSell28,110$11.88$333,946.80View SEC Filing  
3/11/2015Jeffrey Alan HawkinsSVPSell6,832$12.01$82,052.32View SEC Filing  
3/10/2015Jennifer Anne WilliamsSVPSell722$11.83$8,541.26View SEC Filing  
3/10/2015Michael KagnoffDirectorBuy5,000$11.84$59,200.00View SEC Filing  
3/9/2015Ingo ChakravartySVPSell3,310$12.06$39,918.60View SEC Filing  
1/22/2015Hany MassaranyCEOSell5,982$12.88$77,048.16View SEC Filing  
1/7/2015Hany MassaranyCEOSell4,858$13.00$63,154.00View SEC Filing  
12/16/2014Kevin C OboyleDirectorSell291$12.40$3,608.40View SEC Filing  
12/15/2014Eric StierSVPSell235$12.51$2,939.85View SEC Filing  
12/15/2014Hany MassaranyCEOSell1,700$12.51$21,267.00View SEC Filing  
12/4/2014Hany MassaranyCEOSell3,300$12.06$39,798.00View SEC Filing  
12/4/2014Jeffrey Alan HawkinsSVPSell1,350$12.06$16,281.00View SEC Filing  
10/31/2014Jon Faiz KayyemSVPSell6,000$11.01$66,060.00View SEC Filing  
10/8/2014Hany MassaranyCEOSell5,804$9.00$52,236.00View SEC Filing  
10/7/2014Michael GleesonSVPSell55$9.10$500.50View SEC Filing  
9/12/2014Hany MassaranyCEOSell1,678$9.86$16,545.08View SEC Filing  
9/5/2014Hany MassaranyCEOSell3,795$10.04$38,101.80View SEC Filing  
9/5/2014Michael GleesonSVPSell1,833$10.04$18,403.32View SEC Filing  
8/7/2014Michael GleesonSVPSell52$11.15$579.80View SEC Filing  
7/1/2014Jon Faiz KayyemSVPSell6,000$13.60$81,600.00View SEC Filing  
6/11/2014Hany MassaranyCEOSell1,115$11.64$12,978.60View SEC Filing  
6/5/2014Jon Faiz KayyemSVPSell1,483$10.69$15,853.27View SEC Filing  
6/3/2014Hany MassaranyCEOSell2,700$10.67$28,809.00View SEC Filing  
5/29/2014Kevin C OboyleDirectorSell1,603$10.98$17,600.94View SEC Filing  
5/28/2014Jon Faiz KayyemSVPSell6,000$11.06$66,360.00View SEC Filing  
5/8/2014Richard SlanskyCFOSell2,302$9.26$21,316.5279,534View SEC Filing  
4/9/2014Hany MassaranyCEOSell3,985$9.87$39,331.95195,583View SEC Filing  
3/26/2014Jennifer Anne WilliamsSVPSell30,195$9.97$301,044.15185,023View SEC Filing  
3/5/2014Jon Faiz KayyemSVPSell7,355$12.46$91,643.3098,800View SEC Filing  
1/16/2014Jon Faiz KayyemSVPSell50,000$14.05$702,500.00106,155View SEC Filing  
1/7/2014Hany MassaranyCEOSell4,698$13.31$62,530.38229,772View SEC Filing  
12/6/2013Michael GleesonSVPSell2,211$11.14$24,630.54185,649View SEC Filing  
12/4/2013Hany MassaranyCEOSell3,968$11.14$44,203.52240,816View SEC Filing  
10/9/2013Hany MassaranyCEOSell3,925$12.05$47,296.25247,693View SEC Filing  
10/1/2013Jon Faiz KayyemSVPSell6,000$12.14$72,840.00View SEC Filing  
9/4/2013Jeffrey Alan HawkinsSVPSell1,890$11.60$21,924.0094,639View SEC Filing  
9/3/2013Hany MassaranyCEOSell2,354$11.60$27,306.40506,559View SEC Filing  
9/3/2013Jon Faiz KayyemSVPSell1,545$11.60$17,922.00106,806View SEC Filing  
8/20/2013Jon Faiz KayyemSVPSell1,310$10.15$13,296.50108,351View SEC Filing  
7/1/2013Jon Faiz KayyemSVPSell6,000$10.40$62,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GenMark Diagnostics (NASDAQ GNMK) News Headlines

Source:
DateHeadline
Needham & Company LLC Reaffirms "Buy" Rating for GenMark Diagnostics (GNMK)Needham & Company LLC Reaffirms "Buy" Rating for GenMark Diagnostics (GNMK)
www.americanbankingnews.com - April 24 at 8:54 AM
GenMark Diagnostics (GNMK) to Release Earnings on MondayGenMark Diagnostics (GNMK) to Release Earnings on Monday
www.americanbankingnews.com - April 23 at 8:26 AM
GenMark Diagnostics (GNMK) Cut to Sell at BidaskClubGenMark Diagnostics (GNMK) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 18 at 6:22 PM
GenMark Diagnostics Schedules First Quarter Financial Results Conference Call for May 1, 2018GenMark Diagnostics Schedules First Quarter Financial Results Conference Call for May 1, 2018
finance.yahoo.com - April 17 at 6:01 PM
GenMark Diagnostics (GNMK) Stock Rating Upgraded by BidaskClubGenMark Diagnostics (GNMK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 16 at 8:40 PM
 Brokerages Anticipate GenMark Diagnostics, Inc (GNMK) Will Announce Quarterly Sales of $17.35 Million Brokerages Anticipate GenMark Diagnostics, Inc (GNMK) Will Announce Quarterly Sales of $17.35 Million
www.americanbankingnews.com - April 14 at 5:35 AM
GenMark Diagnostics, Inc (GNMK) SVP Sells $54,600.00 in StockGenMark Diagnostics, Inc (GNMK) SVP Sells $54,600.00 in Stock
www.americanbankingnews.com - April 13 at 7:11 PM
This Mornings Technical Outlook on Medical Equipment Stocks -- Edwards Lifesciences, GenMark Diagnostics, Globus Medical, and InspireMDThis Morning's Technical Outlook on Medical Equipment Stocks -- Edwards Lifesciences, GenMark Diagnostics, Globus Medical, and InspireMD
www.bizjournals.com - April 13 at 8:15 AM
GenMark Diagnostics (GNMK) "Buy" Rating Reaffirmed at Canaccord GenuityGenMark Diagnostics' (GNMK) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - April 12 at 11:52 PM
 Brokerages Expect GenMark Diagnostics, Inc (GNMK) to Post -$0.21 EPS Brokerages Expect GenMark Diagnostics, Inc (GNMK) to Post -$0.21 EPS
www.americanbankingnews.com - April 12 at 1:13 AM
BidaskClub Downgrades GenMark Diagnostics (GNMK) to SellBidaskClub Downgrades GenMark Diagnostics (GNMK) to Sell
www.americanbankingnews.com - April 10 at 3:54 PM
GenMark Diagnostics (GNMK) Upgraded by BidaskClub to "Buy"GenMark Diagnostics (GNMK) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 10 at 10:25 AM
Cramer Remix: Ignoring Washington negatives could benefit...Cramer Remix: Ignoring Washington negatives could benefit...
finance.yahoo.com - April 10 at 8:18 AM
GenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Buy" from AnalystsGenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 8 at 7:50 AM
GenMark Diagnostics (GNMK) Stock Rating Lowered by BidaskClubGenMark Diagnostics (GNMK) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
GenMark Diagnostics (GNMK) Earns Buy Rating from Canaccord GenuityGenMark Diagnostics (GNMK) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - April 4 at 12:34 AM
GenMark Diagnostics (GNMK) Stock Rating Lowered by Zacks Investment ResearchGenMark Diagnostics (GNMK) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 1 at 2:38 PM
GenMark Diagnostics (GNMK) PT Set at $11.00 by BTIG ResearchGenMark Diagnostics (GNMK) PT Set at $11.00 by BTIG Research
www.americanbankingnews.com - March 27 at 8:34 PM
GenMark Diagnostics (GNMK) Rating Increased to Buy at BidaskClubGenMark Diagnostics (GNMK) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 27 at 5:10 PM
GenMark Diagnostics (GNMK) Upgraded by BidaskClub to SellGenMark Diagnostics (GNMK) Upgraded by BidaskClub to Sell
www.americanbankingnews.com - March 26 at 5:58 PM
-$0.21 EPS Expected for GenMark Diagnostics, Inc (GNMK) This Quarter-$0.21 EPS Expected for GenMark Diagnostics, Inc (GNMK) This Quarter
www.americanbankingnews.com - March 26 at 3:24 AM
Brokers Set Expectations for GenMark Diagnostics, Incs Q2 2018 Earnings (GNMK)Brokers Set Expectations for GenMark Diagnostics, Inc's Q2 2018 Earnings (GNMK)
www.americanbankingnews.com - March 20 at 8:26 AM
GenMark Diagnostics, Inc (GNMK) Given Consensus Rating of "Hold" by BrokeragesGenMark Diagnostics, Inc (GNMK) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 14 at 1:10 PM
GenMark Diagnostics (GNMK) Raised to "Sell" at BidaskClubGenMark Diagnostics (GNMK) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - March 11 at 5:59 PM
$17.53 Million in Sales Expected for GenMark Diagnostics, Inc (GNMK) This Quarter$17.53 Million in Sales Expected for GenMark Diagnostics, Inc (GNMK) This Quarter
www.americanbankingnews.com - March 10 at 2:56 AM
Head to Head Comparison: ResMed (RMD) & GenMark Diagnostics (GNMK)Head to Head Comparison: ResMed (RMD) & GenMark Diagnostics (GNMK)
www.americanbankingnews.com - March 9 at 9:09 AM
Zacks: Brokerages Anticipate GenMark Diagnostics, Inc (GNMK) Will Post Earnings of -$0.21 Per ShareZacks: Brokerages Anticipate GenMark Diagnostics, Inc (GNMK) Will Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - March 8 at 7:11 PM
Blog Exposure - Zimmer Biomet Showcased New Product and Service Innovations at American Academy of Orthopaedic Surgeons Annual Meeting 2018Blog Exposure - Zimmer Biomet Showcased New Product and Service Innovations at American Academy of Orthopaedic Surgeons Annual Meeting 2018
finance.yahoo.com - March 8 at 8:16 AM
Free Post Earnings Research Report: Steris’ Revenues Grew 2%; Adjusted EPS Advanced 14%Free Post Earnings Research Report: Steris’ Revenues Grew 2%; Adjusted EPS Advanced 14%
finance.yahoo.com - March 7 at 8:12 AM
Whats Happening With These Medical Equipment Stocks? -- GenMark Diagnostics, Globus Medical, Masimo, and Natus MedicalWhat's Happening With These Medical Equipment Stocks? -- GenMark Diagnostics, Globus Medical, Masimo, and Natus Medical
www.prnewswire.com - March 6 at 8:11 AM
GenMark Diagnostics, Inc (GNMK) Director Buys $42,200.00 in StockGenMark Diagnostics, Inc (GNMK) Director Buys $42,200.00 in Stock
www.americanbankingnews.com - March 5 at 7:34 PM
FY2018 EPS Estimates for GenMark Diagnostics, Inc (GNMK) Decreased by William BlairFY2018 EPS Estimates for GenMark Diagnostics, Inc (GNMK) Decreased by William Blair
www.americanbankingnews.com - March 2 at 12:50 PM
Canaccord Genuity Lowers GenMark Diagnostics (GNMK) Price Target to $8.00Canaccord Genuity Lowers GenMark Diagnostics (GNMK) Price Target to $8.00
www.americanbankingnews.com - February 28 at 5:52 PM
GenMark Diagnostics (GNMK) Announces Quarterly  Earnings Results, Meets EstimatesGenMark Diagnostics (GNMK) Announces Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - February 28 at 10:58 AM
Insider Selling: GenMark Diagnostics, Inc (GNMK) SVP Sells 4,911 Shares of StockInsider Selling: GenMark Diagnostics, Inc (GNMK) SVP Sells 4,911 Shares of Stock
www.americanbankingnews.com - February 27 at 9:46 PM
GenMark Diagnostics, Inc (GNMK) CFO Sells $26,166.75 in StockGenMark Diagnostics, Inc (GNMK) CFO Sells $26,166.75 in Stock
www.americanbankingnews.com - February 27 at 9:46 PM
GenMark Diagnostics, Inc (GNMK) Insider Hany Massarany Sells 17,300 SharesGenMark Diagnostics, Inc (GNMK) Insider Hany Massarany Sells 17,300 Shares
www.americanbankingnews.com - February 27 at 9:46 PM
GenMark Diagnostics Reports Fourth Quarter and Full Year 2017 ResultsGenMark Diagnostics Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 27 at 5:58 PM
$15.82 Million in Sales Expected for GenMark Diagnostics, Inc (GNMK) This Quarter$15.82 Million in Sales Expected for GenMark Diagnostics, Inc (GNMK) This Quarter
www.americanbankingnews.com - February 22 at 3:02 PM
Scott Mendel Sells 2,304 Shares of GenMark Diagnostics, Inc (GNMK) StockScott Mendel Sells 2,304 Shares of GenMark Diagnostics, Inc (GNMK) Stock
www.americanbankingnews.com - February 21 at 9:38 PM
GenMark Diagnostics, Inc (GNMK) SVP Sells $22,646.80 in StockGenMark Diagnostics, Inc (GNMK) SVP Sells $22,646.80 in Stock
www.americanbankingnews.com - February 21 at 9:38 PM
Hany Massarany Sells 6,584 Shares of GenMark Diagnostics, Inc (GNMK) StockHany Massarany Sells 6,584 Shares of GenMark Diagnostics, Inc (GNMK) Stock
www.americanbankingnews.com - February 21 at 9:38 PM
GenMark Diagnostics to Present at Upcoming Investor ConferencesGenMark Diagnostics to Present at Upcoming Investor Conferences
finance.yahoo.com - February 21 at 5:30 PM
Zacks: Brokerages Expect GenMark Diagnostics, Inc (GNMK) to Post -$0.24 Earnings Per ShareZacks: Brokerages Expect GenMark Diagnostics, Inc (GNMK) to Post -$0.24 Earnings Per Share
www.americanbankingnews.com - February 20 at 3:08 AM
GenMark Diagnostics (GNMK) Set to Announce Quarterly Earnings on MondayGenMark Diagnostics (GNMK) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - February 19 at 4:30 AM
GenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Hold" from AnalystsGenMark Diagnostics, Inc (GNMK) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 17 at 9:46 AM
Critical Analysis: GenMark Diagnostics (GNMK) vs. Alliance HealthCare Services (AIQ)Critical Analysis: GenMark Diagnostics (GNMK) vs. Alliance HealthCare Services (AIQ)
www.americanbankingnews.com - February 14 at 12:46 PM
GenMark Diagnostics Schedules Fourth Quarter and Full Year 2017 Financial Results Conference Call for February 27, 2018GenMark Diagnostics Schedules Fourth Quarter and Full Year 2017 Financial Results Conference Call for February 27, 2018
finance.yahoo.com - February 14 at 9:19 AM
Head-To-Head Analysis: Intuitive Surgical (ISRG) & GenMark Diagnostics (GNMK)Head-To-Head Analysis: Intuitive Surgical (ISRG) & GenMark Diagnostics (GNMK)
www.americanbankingnews.com - February 12 at 1:16 AM
GenMark Diagnostics, Inc (GNMK) Expected to Post Quarterly Sales of $15.82 MillionGenMark Diagnostics, Inc (GNMK) Expected to Post Quarterly Sales of $15.82 Million
www.americanbankingnews.com - February 5 at 7:32 AM

SEC Filings

GenMark Diagnostics (NASDAQ:GNMK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GenMark Diagnostics (NASDAQ:GNMK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GenMark Diagnostics (NASDAQ GNMK) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.